21.71
0.01 (0.05%)
| Previous Close | 21.70 |
| Open | 21.73 |
| Volume | 600,569 |
| Avg. Volume (3M) | 556,962 |
| Market Cap | 1,288,430,208 |
| Price / Book | 2.71 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.92 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 21.07 |
| Operating Cash Flow (TTM) | -73.96 M |
| Levered Free Cash Flow (TTM) | -45.43 M |
| Return on Assets (TTM) | -21.36% |
| Return on Equity (TTM) | -31.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Enliven Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.10 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 4.75% |
| % Held by Institutions | 90.86% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Novo Holdings A/S | 30 Sep 2025 | 1,426,260 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KINTZ SAMUEL | - | 21.76 | -12,500 | -272,000 |
| Aggregate Net Quantity | -12,500 | |||
| Aggregate Net Value ($) | -272,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 21.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KINTZ SAMUEL | Officer | 17 Nov 2025 | Automatic sell (-) | 12,500 | 21.76 | 272,000 |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | /C O R R E C T I O N -- Enliven Therapeutics, Inc./ |
| 03 Nov 2025 | Announcement | Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |